Xeris Biopharma Holdings, Inc.
XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodicā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.08
Price-4.04%
-$0.34
1Y
Price
Market Cap
$1.395b
Small
Price/Earnings 3y Avg5y Avg
127.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+14.9%
EBITDA Margin+0.8%
Net Profit Margin+24.3%
Free Cash Flow Margin+14.9%
EBITDA Margin+0.8%
Net Profit Margin+24.3%
Free Cash Flow MarginRevenue
$314.853m
+31.1%
1y CAGR+34.5%
3y CAGR+56.5%
5y CAGREarnings
$12.008m
+71.5%
1y CAGR+39.2%
3y CAGR+35.1%
5y CAGREPS
$0.07
+73.0%
1y CAGR+42.2%
3y CAGR+45.3%
5y CAGRBook Value
$13.011m
$392.013m
Assets$379.002m
Liabilities$37.329m
DebtDebt to Assets
9.5%
1.4x
Debt to EBITDAFree Cash Flow
$47.227m
+152.4%
1y CAGR+76.0%
3y CAGR+57.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company